Indo Us Bio-Tech

Indo Us Bio-Tech Equity

The The Equity of Indo Us Bio-Tech (INDOUS.NS) as of Oct 14, 2026 is 925.34 M INR. In the previous year, The Equity was 785.18 M INR — a change of 17.85% (higher).

Equity

925.34 MINR

YoY

17.85%

Last updated:

In 2026, Indo Us Bio-Tech's equity was 925.34 M INR, a 17.85% increase from the 785.18 M INR equity in the previous year.

The Indo Us Bio-Tech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
139.08 M INR
Jan 1, 2020
164.42 M INR
Jan 1, 2021
215.40 M INR
Jan 1, 2022
385.07 M INR
Jan 1, 2023
544.96 M INR
Jan 1, 2024
627.47 M INR
Jan 1, 2025
785.18 M INR
Jan 1, 2026
925.34 M INR
The Indo Us Bio-Tech Equity history
YEAREquityYoY
925.34 MINR+17.85%
785.18 MINR+25.13%
627.47 MINR+15.14%
544.96 MINR+41.52%
385.07 MINR+78.77%
215.40 MINR+31.01%
164.42 MINR+18.23%
139.08 MINR+181.44%
49.42 MINR+41.49%
34.92 MINR+12.74%
30.98 MINR+6.77%
29.01 MINR+38.16%
21.00 MINR—
Access this data via the Eulerpool API
Get Free API Key

Indo Us Bio-Tech Stock analysis

What does Indo Us Bio-Tech do? Indo Us Bio-Tech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Indo Us Bio-Tech's Equity

Indo Us Bio-Tech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Indo Us Bio-Tech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Indo Us Bio-Tech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Indo Us Bio-Tech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Indo Us Bio-Tech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Indo Us Bio-Tech stock

The Equity of Indo Us Bio-Tech is 925.34 M INR in 2026.

The Equity of Indo Us Bio-Tech changed from 785.18 M INR to 925.34 M INR, representing a 17.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Indo Us Bio-Tech since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Indo Us Bio-Tech historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Indo Us Bio-Tech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Indo Us Bio-Tech